Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Brief Summary: This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.


Options:
A: Arm Label: Olaparib+ paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Paclitaxel | Arm Label: Placebo+paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib+ paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Olaparib+ paclitaxel, Placebo+paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+paclitaxel
B: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
C: Arm Label: Arm N - Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N-I, Level 1: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2b: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2c: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cobimetinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm N - Nivolumab, Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib
D: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel

Answer: D